CA3220239A1 - A super-trail molecule comprising two trail trimers - Google Patents

A super-trail molecule comprising two trail trimers Download PDF

Info

Publication number
CA3220239A1
CA3220239A1 CA3220239A CA3220239A CA3220239A1 CA 3220239 A1 CA3220239 A1 CA 3220239A1 CA 3220239 A CA3220239 A CA 3220239A CA 3220239 A CA3220239 A CA 3220239A CA 3220239 A1 CA3220239 A1 CA 3220239A1
Authority
CA
Canada
Prior art keywords
trail
fusion polypeptide
cancer
super
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3220239A
Other languages
English (en)
French (fr)
Inventor
Xinguo QIAN
Wei Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING ANXINHUAIDE BIOTECH Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3220239A1 publication Critical patent/CA3220239A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Lubricants (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3220239A 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers Pending CA3220239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/096498 2021-05-27
CN2021096498 2021-05-27
PCT/CN2022/095472 WO2022247923A1 (en) 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers

Publications (1)

Publication Number Publication Date
CA3220239A1 true CA3220239A1 (en) 2022-12-01

Family

ID=84228436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3220239A Pending CA3220239A1 (en) 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers

Country Status (9)

Country Link
US (1) US20240254193A1 (enExample)
EP (1) EP4347665A4 (enExample)
JP (1) JP2024519397A (enExample)
KR (1) KR20240013766A (enExample)
CN (1) CN117396520A (enExample)
AU (1) AU2022280269A1 (enExample)
CA (1) CA3220239A1 (enExample)
IL (1) IL308618A (enExample)
WO (1) WO2022247923A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120475984A (zh) * 2023-01-05 2025-08-12 国家纳米科学中心 Dna-trail复合物及其治疗肿瘤的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
PL3145530T3 (pl) * 2014-04-21 2021-10-18 D&D Pharmatech Inc. Agonisty receptora trail w leczeniu chorób zwłóknieniowych
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
WO2017194442A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2018183671A1 (en) * 2017-03-29 2018-10-04 Tdw Group Protein conjugates

Also Published As

Publication number Publication date
US20240254193A1 (en) 2024-08-01
AU2022280269A1 (en) 2023-11-30
JP2024519397A (ja) 2024-05-10
CN117396520A (zh) 2024-01-12
WO2022247923A1 (en) 2022-12-01
EP4347665A4 (en) 2025-07-30
EP4347665A1 (en) 2024-04-10
KR20240013766A (ko) 2024-01-30
IL308618A (en) 2024-01-01
AU2022280269A9 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
US11717559B2 (en) Interleukin 15 protein complex and use thereof
US10206980B2 (en) IL-15 heterodimeric protein and uses thereof
CN109071679B (zh) 用于靶向的细胞因子递送的组合物和方法
US20180346549A1 (en) Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines and Their Use
US20220370563A1 (en) Methods of administration of il-2 receptor agonists
CA2978526A1 (en) Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
US20230331858A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN116887850A (zh) 双功能性线融合胶原定位的免疫调节分子及其制备方法
CN114746106A (zh) 通过肿瘤中使用il-7融合蛋白增加淋巴细胞数的方法
JP7221545B2 (ja) ホスファチジルセリン標的化融合分子およびそれらの使用方法
JP7690131B2 (ja) Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
WO2022247923A1 (en) A super-trail molecule comprising two trail trimers
WO2008152508A2 (en) Cytokine conjugate
US12168686B2 (en) Method of treating cancer using disulfide-linked trimeric OX40L
CN110498860B (zh) 一种具有抗肿瘤功能的融合蛋白及其制备方法和应用
US20150247135A1 (en) Broad Spectrum ErBB Ligand Binding Molecules and Methods for Preparing and Using Them
HK40101761A (zh) 包含两个trail三聚体的超trail分子
WO2012019192A2 (en) Cell-permeable molecules as growth factor receptor antagonists
CN115666522A (zh) 包含il-2蛋白和cd80蛋白的融合蛋白制剂
CA3242326C (en) Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2026003203A1 (en) Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
US20240417453A1 (en) Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
US11952402B2 (en) Fusion protein containing trail and IgG binding domain and the uses thereof
EP4186928A1 (en) Fusion polypeptide and polypeptide dimer, and use thereof
CN118994357A (zh) 小肽及其在制备治疗癌症药物中的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250519

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250519

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260420